NEWTON, Mass.–(BUSINESS WIRE)–Pinteon Therapeutics, a biotechnology firm targeted on defending neuronal well being by concentrating on neurotoxic types of tau, right now introduced it has obtained a $3 million award from Superior Expertise Worldwide (ATI) to help the corporate’s Section 1 research of PNT001 in hospitalized sufferers with acute traumatic mind damage. ATI is a nonprofit contractor of the U.S. Division of Protection (DOD) that identifies and sources options for the DOD from trade and academia. The funds will likely be awarded as milestone funds because the trial progresses.
“Traumatic mind damage (TBI), which may outcome from blows to the top or publicity to blasts, disrupts regular mind perform and may even result in psychological sickness, making it a severe concern significantly for these within the army. We’re grateful for the DOD’s help as we consider PNT001, our novel tau antibody, for the therapy of TBI,” mentioned Martin Jefson, Ph.D., Pinteon’s chief government officer. “This funding lends help to Pinteon’s strategy as we advance within the clinic throughout a number of tauopathies, with our Section 1b/Section 2 research of PNT001 in Alzheimer’s illness anticipated to start later this yr.”
Pinteon is at present enrolling sufferers within the Section 1 research. Extra info will be discovered on ClinicalTrials.gov (NCT04677829).
Pinteon has additionally shared promising Phase 1 data exhibiting PNT001 was well-tolerated in wholesome volunteers at dose ranges that will present potential therapeutic impact. The corporate expects to provoke a Section 1b/Section 2 research of PNT001 in sufferers with Alzheimer’s illness by the tip of 2021.
About Pinteon Therapeutics
Pinteon Therapeutics is advancing medical research of a novel antibody that goals to interrupt the unfold of poisonous tau and shield and protect mind perform in sufferers with neurodegenerative illness, with a give attention to Alzheimer’s illness and traumatic mind damage. Pinteon’s lead asset, PNT001, is the one antibody in improvement that targets cis-pT231 tau, a neurotoxic epitope that has been recognized in a number of preclinical research as a potent driver of neurodegenerative illness. The corporate reported promising Section 1 security knowledge early in 2021 exhibiting PNT001 was well-tolerated at dose ranges that will present potential therapeutic impact. Pinteon is led by an skilled administration crew with sturdy observe data in CNS drug discovery and improvement and is funded by Morningside Ventures. For extra info, go to pinteon.com.